Dr. Knight joined Chimerix in September 2017 as Vice President of Regulatory Affairs. She has nearly 20 years of regulatory experience in the pharmaceutical industry. Prior to joining Chimerix, Dr. Knight served as executive director of regulatory affairs at Hurley Consulting Associates, where she was responsible for regulatory strategy and implementation for multiple clients. She was previously at Bristol Myers Squibb for ten years which included global regulatory strategy and project management roles in the U.S. and leading a multinational regulatory group in Europe. She also held positions in regulatory affairs at Zymogenetics (acquired by Bristol-Myers Squibb) in Seattle, Washington and at Hoffmann-La Roche, Inc., in Nutley, New Jersey. She has experience with oncology and antiviral new drug approvals (including Yervoy (ipilimumab), Ixempra (ixabepilone) and Fuzeon (enfuvirtide)) in the US, EU, and multiple key global markets. Dr. Knight received a B.S. in Biology and a PharmD at West Virginia University. She was a Rutgers Industrial Pharmacy Post-Doctoral Fellow with Hoffmann-La Roche, Inc., and FDA CDER’s oncology division.
This post was written by tbe_admin